Support AlterNet
Do you value the information you're getting from AlterNet? Please show your support with a tax-deductible donation.
Feedback
Tell us how we're doing.
So Much for Big Pharma's 'Anti-Pot' Pill
Corporate Accountability and WorkPlace:
Hedge Fund Would Rather Shut Down a Plant Than Pay Its Workers a Fair Wage
Art Levine
DrugReporter:
The Supreme Court Resists Drug War Hysteria
Krystal Quinlan
Environment:
Summer Downsizing: 31 Ways to Jumpstart Your Local Economy
Sarah van Gelder
Health and Wellness:
10 Dangerous Household Products You Should Never Use Again
Immigration:
Huron, California May not Exist in a Year
Viji Sundaram
Media and Technology:
Michael Jackson's Death Was Tragic, But He Was Little More Than an Icon of Mediocrity
Alisa Valdes-Rodriguez
Movie Mix:
Up: This Time, Pixar Has Gone Too Far
Eileen Jones
Politics:
Hunter Thompson Knew It Well: Robert McNamara's Vision for America Was Imperial and Elitist
Joe Costello
Reproductive Justice and Gender:
My First Abortion Party
Byard Duncan
Rights and Liberties:
Does a Senior Obama Official Have Unseemly Ties to Notorious Human Rights Abuser Chevron?
Jeremy Scahill
Sex and Relationships:
How to Make Marriage More Than an Arrangement of Love-less, Sexless, Domestic Drudgery
Vanessa Richmond
Take Action:
Ending Indefinite Detention is AlterNet's Top Take Action Campaign of the Week
Byard Duncan
Water:
Energy Industry Threatens Water Quality, Sways Congress With Misleading Data
Abrahm Lustgarten
World:
What Kind of "Hope" Is Obama Offering to Latin American Countries Still Traumatized by U.S. Empire?
Roberto Lovato
An independent U.S. Food and Drug Administration advisory committee determined yesterday that the controversial "anti-pot" pill Rimonabant is unsafe for human consumption in the United States. Sanofi-Aventis' would-be diet aid -- which has been linked to suicidal thoughts, depression and even multiple sclerosis -- counteracts the effects of marijuana and similar naturally occurring chemicals in the body (so-called endocannabinoids), causing users to lose their appetites and, according to the warnings of experts, a host of other unwanted and dangerous side effects.
Rimonabant does not possess a "favorable risk-benefit profile" to warrant U.S. market approval, members of the FDA's Endocrinologic and Metabolic Drug advisory panel determined in a 14-0 vote. Panelists reported that patients prescribed Rimonabant experienced increased incidences of depression, nausea, vomiting, and suicidal tendencies. Adverse neurological symptoms in some patients were also reported.
The expert panel's rejection sent shares of Sanofi stock plummeting and may have worldwide implications. Last summer European regulators gave preliminary approval to the pill, which has now been prescribed to some 100,000 patients under the trade name Acomplia. However, following Wednesday's unanimous decision, representatives of the European Medicines Agency immediately announced that they will begin hearings to consider recalling the drug.
For Sanofi stockholders and analysts, who had predicted that pharmaceutical giant's "anti-pot" pill could one day rake in some $3 billion in annual profits, the news is a disappointing financial setback. But to health experts familiar with the workings of Rimonabant and similar drugs, the FDA panel's decision comes as little surprise and is long overdue.
The dark side of Acomplia
As a weight loss drug, Rimonabant is far from a miracle cure. In controlled studies, patients who ceased taking Rimonabant typically gained their weight back -- implying that the drug may have to be prescribed indefinitely. It's that likelihood, coupled with the drug's reported and potential side effects, that have raised eyebrows among the scientific community.
Because the endocannabinoid system is involved in the regulation of a broad range of primary biological functions -- including appetite, mood regulation, blood pressure, bone density, reproduction, learning capacity, and motor coordination -- some experts are concerned that the long-term use of Rimonabant and/or similar drugs to counteract it could contribute to a host of significant adverse health effects. Animal data appears to substantiate this concern. Newborn mice injected with Rimonabant refuse feeding and often die days after birth. Mice genetically bred to lack certain cannabinoid receptors also suffer from numerous health defects such as cognitive decline, hypoalgesia, decreased locomotor activity and increased mortality compared to healthy controls. Could similar risks await long-term users of Rimonabant?
See more stories tagged with: rimonabant, anti-pot
Paul Armentano is the senior policy analyst for the NORML Foundation in Washington, D.C.
Liked this story? Get top stories in your inbox each week from AlterNet! Sign up now »